Study tiny RNA changes in triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies patterns of microRNA (tiny gene-regulating molecules) in women with triple-negative breast cancer. By comparing these microRNA profiles, the study hopes to better understand the disease and potentially guide future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70
- You have a breast tumor confirmed as cancer that is “triple-negative” on a special lab test (IHC)
- Your tumor is large enough for a needle biopsy (at least 2 cm) and is reachable by ultrasound or exam
- You have not had chemotherapy for this breast cancer, and you are in stage IIA to IIIC
- You can do the study activities and are generally well (ECOG 0 to 1)
- Your key blood, liver, and kidney tests are in acceptable ranges, and your heart ultrasound shows normal pumping (left ejection fraction ≥55%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a standard chemotherapy treatment for Nigerian women with triple-negative breast cancer that has not spread widely. It aims to see how well the treatment works and how safe it is.
This trial tests a new personalized treatment approach (mRNA-lncRNA model) for people with low-risk, early-stage triple-negative breast cancer who have already had surgery. It aims to see if a less intense treatment can work just as well as standard care.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.